Momenta Pharmaceuticals (NASDAQ: MNTA) and China Biologic Products (NASDAQ:CBPO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.
Insider and Institutional Ownership
94.8% of Momenta Pharmaceuticals shares are held by institutional investors. Comparatively, 53.9% of China Biologic Products shares are held by institutional investors. 4.8% of Momenta Pharmaceuticals shares are held by insiders. Comparatively, 2.7% of China Biologic Products shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a summary of recent recommendations for Momenta Pharmaceuticals and China Biologic Products, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|China Biologic Products||0||1||1||0||2.50|
Momenta Pharmaceuticals currently has a consensus target price of $15.63, suggesting a potential downside of 28.65%. China Biologic Products has a consensus target price of $101.00, suggesting a potential upside of 23.11%. Given China Biologic Products’ stronger consensus rating and higher possible upside, analysts plainly believe China Biologic Products is more favorable than Momenta Pharmaceuticals.
Risk and Volatility
Momenta Pharmaceuticals has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500. Comparatively, China Biologic Products has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500.
This table compares Momenta Pharmaceuticals and China Biologic Products’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|China Biologic Products||17.76%||17.29%||14.89%|
Valuation & Earnings
This table compares Momenta Pharmaceuticals and China Biologic Products’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Momenta Pharmaceuticals||$138.88 million||12.24||-$88.09 million||($1.20)||-18.25|
|China Biologic Products||$370.41 million||7.34||$67.94 million||$4.95||16.57|
China Biologic Products has higher revenue and earnings than Momenta Pharmaceuticals. Momenta Pharmaceuticals is trading at a lower price-to-earnings ratio than China Biologic Products, indicating that it is currently the more affordable of the two stocks.
China Biologic Products beats Momenta Pharmaceuticals on 9 of the 13 factors compared between the two stocks.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE. Its biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, as well as other biosimilar candidates. The company's novel therapeutics programs include M254, a hyper-sialylated version of intravenous immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy; M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; and M230, a recombinant trivalent human IgG1 Fc multimer to block tissue damage mediated by immune complexes. It has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
China Biologic Products Company Profile
China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin for intravenous injection products for original and secondary immunoglobulin deficiency, and auto-immune deficiency diseases; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing immune globulin intravenous; human antithrombin III; Caprylate/Chromatography Purified and 20 nm virus filtration; human coagulation factor IX; human cytomegalovirus immunoglobulin; and human fibrin sealant products. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.